Literature DB >> 18164145

Behavioral drug and HIV risk reduction counseling (BDRC) with abstinence-contingent take-home buprenorphine: a pilot randomized clinical trial.

M C Chawarski1, M Mazlan, R S Schottenfeld.   

Abstract

This pilot randomized clinical trial evaluated whether the efficacy of office-based buprenorphine maintenance treatment (BMT), provided with limited counseling or oversight of medication adherence is improved by the addition of individual drug counseling and abstinence-contingent take-home doses of buprenorphine. After a 2-week buprenorphine and stabilization period, heroin dependent individuals (n=24) in Muar, Malaysia were randomly assigned to Standard Services BMT (physician administered advice and support, and weekly, non-contingent medication pick-up) or Enhanced Services (nurse-delivered manual-guided behavioral drug and HIV risk reduction counseling (BDRC) and abstinence-contingent take-home buprenorphine (ACB), 7 day supply maximum). Outcomes included retention, proportion of opioid-negative urine tests, self-reported drug use, and self-reported HIV risk behaviors. 12/12 (100%) of Enhanced Services and 11/12 (92%) of Standard Services participants completed the entire protocol. The proportion of opioid-negative urine tests increased significantly over time for both groups (p<0.001), and the reductions were significantly greater in the Enhanced Services group (p<0.05); Enhanced Services group achieved higher overall proportions of opiate negative urine toxicology tests (87% vs. 69%, p=0.04) and longer periods of consecutive abstinence from opiates (10.3 weeks vs. 7.8 weeks, p=0.154). Both groups significantly reduced HIV risk behaviors during treatment (p<0.05), but the difference between Enhanced and Standard Services (26% vs. 17% reductions from the baseline levels, respectively) was not statistically significant (p=0.9). Manual-guided behavioral drug and HIV risk reduction counseling and abstinence-contingent take-home buprenorphine appear promising for adding to the efficacy of office-based BMT provided with limited drug counseling and medication oversight.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18164145     DOI: 10.1016/j.drugalcdep.2007.11.008

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  13 in total

1.  Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058.

Authors:  David S Metzger; Deborah Donnell; David D Celentano; J Brooks Jackson; Yiming Shao; Apinun Aramrattana; Liu Wei; Liping Fu; Jun Ma; Gregory M Lucas; Marek Chawarski; Yuhua Ruan; Paul Richardson; Katherine Shin; Ray Y Chen; Jeremy Sugarman; Bonnie J Dye; Scott M Rose; Geetha Beauchamp; David N Burns
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

Review 2.  The globalization of addiction research: capacity-building mechanisms and selected examples.

Authors:  Richard A Rawson; George Woody; Thomas F Kresina; Steven Gust
Journal:  Harv Rev Psychiatry       Date:  2015 Mar-Apr       Impact factor: 3.732

3.  Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: A randomized controlled trial.

Authors:  Richard S Schottenfeld; Marek C Chawarski; Mehmet Sofuoglu; Weng-Tink Chooi; Norzarina M Zaharim; M Azhar M Yasin; Imran Ahmad; Sharifah Zubaidiah Syed Jaapar; B Kasinather Vicknasingam
Journal:  Drug Alcohol Depend       Date:  2018-03-10       Impact factor: 4.492

4.  Counseling and directly observed medication for primary care buprenorphine maintenance: a pilot study.

Authors:  Brent A Moore; Declan T Barry; Lynn E Sullivan; Patrick G Oʼconnor; Christopher J Cutter; Richard S Schottenfeld; David A Fiellin
Journal:  J Addict Med       Date:  2012-09       Impact factor: 3.702

Review 5.  Retention of participants in medication-assisted programs in low- and middle-income countries: an international systematic review.

Authors:  Jonathan Feelemyer; Don Des Jarlais; Kamyar Arasteh; Abu S Abdul-Quader; Holly Hagan
Journal:  Addiction       Date:  2013-08-15       Impact factor: 6.526

6.  Behavioral drug and HIV risk reduction counseling (BDRC) in MMT programs in Wuhan, China: a pilot randomized clinical trial.

Authors:  M C Chawarski; W Zhou; R S Schottenfeld
Journal:  Drug Alcohol Depend       Date:  2010-12-14       Impact factor: 4.492

7.  Costs of addressing heroin addiction in Malaysia and 32 comparable countries worldwide.

Authors:  Jennifer Prah Ruger; Marek Chawarski; Mahmud Mazlan; Craig Luekens; Nora Ng; Richard Schottenfeld
Journal:  Health Serv Res       Date:  2011-10-18       Impact factor: 3.402

Review 8.  A Systematic Review of the Effects of Behavioral Counseling on Sexual Risk Behaviors and HIV/STI Prevalence in Low- and Middle-Income Countries.

Authors:  Kristyn Zajac; Caitlin E Kennedy; Virginia A Fonner; Kevin S Armstrong; Kevin R O'Reilly; Michael D Sweat
Journal:  AIDS Behav       Date:  2015-07

9.  Adjunct interventions to standard medical management of buprenorphine in outpatient settings: A systematic review of the evidence.

Authors:  Jessica J Wyse; Benjamin J Morasco; Jacob Dougherty; Beau Edwards; Devan Kansagara; Adam J Gordon; P Todd Korthuis; Anaïs Tuepker; Stephan Lindner; Katherine Mackey; Beth Williams; Anders Herreid-O'Neill; Robin Paynter; Travis I Lovejoy
Journal:  Drug Alcohol Depend       Date:  2021-07-29       Impact factor: 4.852

10.  Cost-effectiveness of buprenorphine and naltrexone treatments for heroin dependence in Malaysia.

Authors:  Jennifer Prah Ruger; Marek Chawarski; Mahmud Mazlan; Nora Ng; Richard Schottenfeld
Journal:  PLoS One       Date:  2012-12-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.